DGAP-News: Apricus Biosciences Strengthens Vitaros(R) and Nexact(R) Patent Estate With Two New Patent Allowances Apricus Biosciences, Inc.
25.05.2012 19:20
---------------------------------------------------------------------------
SAN DIEGO, 2012-05-25 19:20 CEST (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio' or the 'Company') (Nasdaq:APRI)
(http://www.apricusbio.com), announced today that the Canadian Intellectual
Property Office issued a Notice of Allowance for a Canadian patent on certain
methods of manufacture for the Company's platform NexACT(r) drug delivery
technology.
Specifical ...
DGAP-News: Apricus Biosciences Granted Regulatory Guidance With FDA for MycoVa(TM) for the Treatment of Onychomycosis Apricus Biosciences, Inc.
22.05.2012 16:13
---------------------------------------------------------------------------
SAN DIEGO, 2012-05-22 16:13 CEST (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio' or the 'Company') (Nasdaq:APRI)
(http://www.apricusbio.com) announced today that the United States ('U.S.')
Food and Drug Administration ('FDA') has granted the Company's request for Type
C regulatory guidance from the agency for MycoVa(tm), the Company's topical ...
DGAP-News: Apricus Biosciences Granted Regulatory Meeting With FDA for Femprox(R) for the Treatment of Female Sexual Arousal Disorder Apricus Biosciences, Inc.
21.05.2012 15:35
---------------------------------------------------------------------------
SAN DIEGO, 2012-05-21 15:35 CEST (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio' or the 'Company') (Nasdaq:APRI)
(http://www.apricusbio.com) announced today that the United States ('U.S.')
Food and Drug Administration ('FDA') has granted the Company's request for a
Type C meeting to obtain regulatory guidance from the agency for Femprox(r), the
Company's topical ...
DGAP-News: Apricus Biosciences to Present at the 11th Annual JMP Securities Research Conference Apricus Biosciences, Inc.
14.05.2012 15:42
---------------------------------------------------------------------------
SAN DIEGO, 2012-05-14 15:42 CEST (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio') (Nasdaq:APRI) announced today that
Edward Cox, Vice President Corporate Development and Investor Relations, will
present at the 11th Annual JMP Securities Research Conference, being held at
The Ritz Carlton in San Francisco, California. Apricus Biosciences'
presentation will take pl ...
DGAP-News: Health Canada Grants Apricus Biosciences Pre-NDS Meeting for MycoVa(TM) for the Treatment of Onychomycosis Apricus Biosciences, Inc.
11.05.2012 15:55
---------------------------------------------------------------------------
SAN DIEGO, 2012-05-11 15:55 CEST (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio' or the 'Company') (Nasdaq:APRI)
(http://www.apricusbio.com) announced today that Health Canada has granted the
Company's request for a Pre-New Drug Submission ('Pre-NDS') meeting to obtain
regulatory guidance from the agency for MycoVa(tm), the Company's topical
treatment for onychom ...
DGAP-News: Apricus Biosciences Announces First Quarter 2012 Financial Results Conference Call and Provides Corporate Update Apricus Biosciences, Inc.
08.05.2012 15:49
---------------------------------------------------------------------------
Conference Call/Webcast to be Held Thursday, May 10, 2012 at 4:30 p.m. ET
SAN DIEGO, 2012-05-08 15:49 CEST (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio') (Nasdaq:APRI) announced today that
management will hold a conference call to discuss its first quarter 2012
financial results and ongoing corporate activities on Thursday, May 10, 2012 at
4:30 p.m. ET. The Co ...
DGAP-News: Health Canada Grants Apricus Biosciences Pre-NDS Meeting for Femprox for Female Sexual Arousal Disorder Apricus Biosciences, Inc.
07.05.2012 16:10
---------------------------------------------------------------------------
SAN DIEGO, 2012-05-07 16:10 CEST (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio' or the 'Company') (Nasdaq:APRI)
(http://www.apricusbio.com) announced today that Health Canada has granted the
Company's request for a Pre-New Drug Submission ('Pre-NDS') meeting to obtain
regulatory guidance from the agency for Femprox(r), its topical alprostadil cream
for the treat ...
DGAP-News: Apricus Biosciences Announces Poster Presentation of Femprox(R) Phase III Clinical Data at American Urological Association Annual Meeting Apricus Biosciences, Inc.
04.05.2012 16:05
---------------------------------------------------------------------------
SAN DIEGO, 2012-05-04 16:05 CEST (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio' or the 'Company') (Nasdaq:APRI)
(http://www.apricusbio.com) announced today a poster titled, 'Updated analyses
of randomized, double-blind, Phase 3 study of Femprox(r), an alprostadil cream
with a novel transdermal delivery technology for the treatment of female sexual
arousal disord ...
DGAP-News: Apricus Biosciences Receives Notice of Issuance for First Prevonco(TM) Patent in the United States Apricus Biosciences, Inc.
26.04.2012 18:00
---------------------------------------------------------------------------
SAN DIEGO, 2012-04-26 18:00 CEST (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio' or the 'Company') (Nasdaq:APRI)
(http://www.apricusbio.com), announced today that the Company received an Issue
Notification from the United States Patent and Trademark Office for U.S. Patent
Application No. 12/138,603 entitled 'Thiazole Compounds, and Compositions and
Methods Using ...
DGAP-News: Apricus Biosciences Announces Allowance of a NexACT(R) Technology-Based Patent in Europe for the Manufacture of DDAIP Apricus Biosciences, Inc.
22.03.2012 12:00
---------------------------------------------------------------------------
SAN DIEGO, 2012-03-22 12:00 CET (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio' or the 'Company') (Nasdaq:APRI)
(http://www.apricusbio.com), announced today that the European Patent Office
('EPO') has issued an official decision to allow the Company's patent
application entitled, 'Method for the Manufacture of Dodecyl
2-(N,N-Dimenthylamino)-Propionate.' The allow ...
DGAP-News: Apricus Biosciences, San Diego Hospice and The Institute for Palliative Medicine Announce a Broad Clinical Research Program Using NexACT(R) Technology Apricus Biosciences, Inc.
14.03.2012 15:05
---------------------------------------------------------------------------
SAN DIEGO, 2012-03-14 15:05 CET (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio' or the 'Company') (Nasdaq:APRI)
(http://www.apricusbio.com), San Diego Hospice (the 'Hospice') and The
Institute for Palliative Medicine today announced the signing of a clinical
development collaboration to study the use of the Company's NexACT(r) Technology
in the hospice setting. C ...
DGAP-News: Apricus Biosciences CEO is Interviewed on CDTV.Net Apricus Biosciences, Inc.
06.03.2012 16:01
---------------------------------------------------------------------------
Apricus Metamorphoses From a Clinical Stage Development Company to a Commercial
Stage Specialty Pharmaceuticals Company
SAN DIEGO, 2012-03-06 16:01 CET (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. (Nasdaq:APRI) (www.apricusbio.com) Chief Executive
Officer Dr. Bassam Damaj said in an interview on CDTV.net that his company has
acquired its own sales force, has nearly $25 mil ...
DGAP-News: Apricus Biosciences Announces Shareholder Update With New Focus as a Commercially-Driven Specialty Pharmaceutical Company Apricus Biosciences, Inc.
16.02.2012 16:06
---------------------------------------------------------------------------
Company CEO Sets Goal to Grow Revenues in 2012 and Long-Term
SAN DIEGO, 2012-02-16 16:06 CET (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio' or the 'Company') (Nasdaq:APRI)
announced today a corporate update to address Company activities and expected
near-term events.
Dr. Bassam Damaj, Chairman, President and Chief Executive Officer of Apricus
Bio, stated, 'We ...
DGAP-News: Apricus Bioscience's Wholly-Owned Subsidiary NexMed (USA) Signs Exclusive German Collaboration for Vitaros(R) for Erectile Dysfunction Apricus Biosciences, Inc.
16.02.2012 01:19
---------------------------------------------------------------------------
SAN DIEGO, 2012-02-16 01:19 CET (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio' or the 'Company') (Nasdaq:APRI)
(http://www.apricusbio.com) announced today that its wholly-owned subsidiary
NexMed(USA), Inc. has signed with Sandoz, a division of Novartis, an exclusive
collaboration for Germany to market Apricus Bio's Vitaros(r) drug for the
treatment of erectile d ...
DGAP-News: Apricus Biosciences Announces Acquisition of NitroMist(TM) Rights Outside North America Apricus Biosciences, Inc.
03.02.2012 15:41
---------------------------------------------------------------------------
SAN DIEGO, 2012-02-03 15:41 CET (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio' or the 'Company') (Nasdaq:APRI)
(http://www.apricusbio.com) announced today the execution of a binding term
sheet with NovaDel Pharma Inc. ('NovaDel') (OTCBB:NVDL) for the sale and
license of rights in territories outside of the United States, Canada and
Mexico to NovaDel's NitroMist( ...
DGAP-News: Apricus Biosciences Announces Allowance of Israeli Patent, Expanding Its Patent Portfolio for the Topical Treatment of Premature Ejaculation Apricus Biosciences, Inc.
17.01.2012 16:03
---------------------------------------------------------------------------
SAN DIEGO, 2012-01-17 16:03 CET (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio' or the 'Company') (Nasdaq:APRI)
(http://www.apricusbio.com) announced today that the Israeli Patent Office
recently issued a Notice of Allowance to grant a patent for the Company's
development of a topical cream utilizing vasoactive prostaglandin E to treat
premature ejaculation ('PE' ...
DGAP-News: Apricus Biosciences and Elis Pharma Sign License Agreement for MycoVa(TM) in the Middle East and the Gulf Apricus Biosciences, Inc.
10.01.2012 15:51
---------------------------------------------------------------------------
Apricus Bio to Receive up to $2.1 Million, Plus Royalties
SAN DIEGO and DUBAI, United Arab Emirates, 2012-01-10 15:51 CET (GLOBE
NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio') (www.apricusbio.com) (Nasdaq:APRI)
and Elis Pharmaceuticals ('Elis') (www.elispharmaceuticals.com), announced
today that the two companies have entered into a licensing agreement granting
Elis ...
DGAP-News: Apricus Biosciences to Webcast Today's Presentation at Biotech Showcase(TM) 2012 in San Francisco Apricus Biosciences, Inc.
09.01.2012 22:22
---------------------------------------------------------------------------
SAN DIEGO, 2012-01-09 22:22 CET (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio') (Nasdaq:APRI)
(http://www.apricusbio.com) announced today that Chairman, President and Chief
Executive Officer, Dr. Bassam Damaj's previously announced presentation, taking
place at 2:30pm Pacific Time today, at Biotech Showcase(tm) 2012 at the Park
Wyndham Hotel in San Francisco, Ca ...
DGAP-News: Apricus Biosciences and Abbott Sign Exclusive Agreement to Market Vitaros(R) (Alprostadil) in Canada Apricus Biosciences, Inc.
09.01.2012 18:29
---------------------------------------------------------------------------
SAN DIEGO, 2012-01-09 18:29 CET (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio') (Nasdaq:APRI)
(http://www.apricusbio.com) announced today that it has entered into an
exclusive licensing agreement granting Abbott Laboratories Limited a global,
diversified healthcare company, the exclusive rights to market Vitaros(r)
(alprostadil), Apricus Bio's treatment for erec ...
DGAP-News: Apricus Biosciences CEO, Dr. Bassam Damaj, to Present at Biotech Showcase(TM) 2012 in San Francisco Apricus Biosciences, Inc.
04.01.2012 15:49
---------------------------------------------------------------------------
SAN DIEGO, 2012-01-04 15:49 CET (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio') (Nasdaq:APRI)
(http://www.apricusbio.com) announced today that Dr. Bassam Damaj, Chairman,
President and Chief Executive Officer, will present a company overview at
Biotech Showcase(tm) 2012, being held at the Park Wyndham Hotel in San Francisco,
California, from January 9 to January ...
DGAP-News: Apricus Biosciences Completes Acquisition of Topotarget USA, Inc. Apricus Biosciences, Inc.
29.12.2011 18:30
---------------------------------------------------------------------------
To Rename the Newly Acquired Company, Apricus Pharmaceuticals USA, Inc.
SAN DIEGO, Dec. 29, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc.
('Apricus Bio') (Nasdaq:APRI) (http://www.apricusbio.com) announced today the
closing of its acquisition of Topotarget USA, Inc., a subsidiary of Topotarget
A/S, a Danish company listed on the Copenhagen exchange.
Pursuant to the clo ...
DGAP-News: Apricus Biosciences Launches Commercialization Arm With Definitive Agreement to Acquire Topotarget USA Apricus Biosciences, Inc.
16.12.2011 14:00
---------------------------------------------------------------------------
First Acquisition by Apricus Bio of an FDA Approved and Marketed US Drug
SAN DIEGO, 2011-12-16 14:00 CET (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio' or the 'Company') (Nasdaq:APRI)
announced today a definitive agreement to acquire Topotarget USA, Inc.
('Topotarget USA'), a subsidiary of Topotarget A/S, a public Danish company
('Topotarget A/S'). Topotarget U ...
DGAP-News: Apricus Biosciences Press Release Apricus Biosciences, Inc.
15.12.2011 16:18
---------------------------------------------------------------------------
Apricus Biosciences Announces Oral Presentation of Efficacy and Clinical Safety
Data for Vitaros(R) and Femprox(R) at the African Society for Sexual Medicine
Conference
SAN DIEGO, 2011-12-15 16:11 CET (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc.
('Apricus Bio' or the 'Company') (Nasdaq:APRI) announced today the planned,
oral presentation of clinical efficacy and safety dat ...
DGAP-News: Apricus Biosciences, Inc. Press Release Apricus Biosciences, Inc.
12.12.2011 18:16
---------------------------------------------------------------------------
Apricus Biosciences' Vitaros(R) Podium Presentation Named Best Clinical
Presentation 2011 (Male Sexual Disorder) by the Scientific Committee of the
Congress for the European Society of Sexual Medicine Meeting in Milan
SAN DIEGO, 2011-12-12 18:03 CET (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc.
('Apricus Bio' or the 'Company') (Nasdaq:APRI) announced today that its podium
p ...
DGAP-News: Apricus Biosciences Announces Allowance of Additional NexACT(R) Patent in Japan Apricus Biosciences, Inc.
08.12.2011 16:01
---------------------------------------------------------------------------
SAN DIEGO, 2011-12-08 16:01 CET (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio' or the 'Company') (Nasdaq:APRI)
announced today that the Japanese Patent Office has issued an official decision
to allow Japanese patent application entitled, 'Crystalline Salts of Dodecyl
2-(N,N-Dimethylamino)-Propionate.' The patent will cover compositions and
methods related to cry ...
DGAP-News: Apricus Biosciences Announces Appointment of Dr. Kleanthis G. Xanthopoulos to Its Board of Directors Apricus Biosciences, Inc.
21.11.2011 15:51
---------------------------------------------------------------------------
SAN DIEGO, 2011-11-21 15:51 CET (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio' or the 'Company') (Nasdaq:APRI)
announced today that Kleanthis G. Xanthopoulos, Ph.D., President and Chief
Executive Officer of Regulus Therapeutics Inc. ('Regulus'), has been appointed
to the Company's Board of Directors, effective immediately.
Prior to joining Regulus in 2007, Dr. ...
DGAP-News: Apricus Biosciences Announces That Its NexACT(R) Partner Exodos Life Sciences Has Completed Its pre-IND Meeting With the FDA Apricus Biosciences, Inc.
15.11.2011 15:30
---------------------------------------------------------------------------
Exodos Moves Closer to Filing a U.S. Investigational New Drug Application for
Its Topically-Applied Formulation of Ketoprofen for Pain Relief
SAN DIEGO, 2011-11-15 15:30 CET (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio' or the 'Company') (Nasdaq:APRI)
announced today that its NexACT(r) out-licensing partner, Exodos Life Science
Limited Partnership ('Exodos'), ...
DGAP-News: Femprox(R) Phase III Clinical Data From Apricus Biosciences Chosen for a Presentation at the European Society for Sexual Medicine Apricus Biosciences, Inc.
14.11.2011 15:47
---------------------------------------------------------------------------
SAN DIEGO, 2011-11-14 15:47 CET (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio' or the 'Company') (Nasdaq:APRI)
announced today the acceptance of an abstract entitled, 'Age Group Analysis of
a Randomized, Double-blind, Phase 3 study of Femprox(r), a Topical Alprostadil
Cream with a Novel Transdermal Delivery Technology (Nexact(r)) for the Treatment
of Female Sexu ...
DGAP-News: Apricus Biosciences Announces Third Quarter 2011 Financial Results Conference Call Apricus Biosciences, Inc.
11.11.2011 19:16
---------------------------------------------------------------------------
Conference Call/Webcast to be Held Tuesday, November 15, 2011 at 12:00 Noon ET
SAN DIEGO, 2011-11-11 19:16 CET (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio') (Nasdaq:APRI) announced today that
management will hold a conference call to discuss its third quarter 2011
financial results and ongoing corporate activities on Tuesday, November 15,
2011 at 12:00 Noon E ...
DGAP-News: Apricus Biosciences Announces Issuance of Korean Patent, Expanding Its Patent Portfolio for Its Topical Cream to Treat Premature Ejaculation Apricus Biosciences, Inc.
19.10.2011 15:30
---------------------------------------------------------------------------
SAN DIEGO, 2011-10-19 15:30 CEST (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio' or the 'Company') (Nasdaq:APRI)
(http://www.apricusbio.com) announced today that the Korean Patent Office
recently issued a Notice of Allowance to grant a patent for the Company's
development of a topical cream utilizing vasoactive prostaglandin E to treat
premature ejaculation ('PE ...
DGAP-News: Apricus Biosciences Announces New Data Published in the International Journal of Pharmaceutics Confirming Efficiency of NexACT(R) Drug Delivery Technology Apricus Biosciences, Inc.
13.10.2011 17:30
---------------------------------------------------------------------------
SAN DIEGO, 2011-10-13 17:30 CEST (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio' or the 'Company') (Nasdaq:APRI)
(http://www.apricusbio.com) announced today the publication of an article in
the peer-reviewed International Journal of Pharmaceutics, entitled,
'Transdermal and Transbuccal Drug Delivery Systems: Enhancement Using
Iontophoretic and Chemical Approaches ...
DGAP-News: Apricus Biosciences to Present Poster of Femprox(R) Phase III Clinical Data at Upcoming Industry Conference Apricus Biosciences, Inc.
06.10.2011 15:52
---------------------------------------------------------------------------
SAN DIEGO, 2011-10-06 15:52 CEST (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio' or the 'Company') (Nasdaq:APRI)
(http://www.apricusbio.com) announced today that the submission of an abstract
entitled, 'Results of a Phase III Clinical Trial for Female Sexual Arousal
Disorder ('FSAD') with Femprox(r), a Topical Alprostadil 0.4% Cream with a Novel
Transdermal Deliv ...
DGAP-News: Apricus Biosciences Announces Korean Patent Approval for MycoVa(TM) for Nail Fungus Apricus Biosciences, Inc.
03.10.2011 17:03
---------------------------------------------------------------------------
CEO Foresees Expanded Asian Patent Coverage for MycoVa(TM) Product
SAN DIEGO, 2011-10-03 17:03 CEST (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio' or the 'Company') (Nasdaq:APRI)
(http://www.apricusbio.com) announced today that the Korean Patent Office will
grant a patent for MycoVa(tm), indicated for the treatment of onychomycosis
(commonly referred to as nail ...
DGAP-News: Apricus Biosciences to Provide Overview of Rx and Consumer Healthcare Divisions at the 11th Annual Biotech in Europe Investor Forum Apricus Biosciences, Inc.
09.09.2011 20:51
---------------------------------------------------------------------------
SAN DIEGO, 2011-09-09 20:51 CEST (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio') (Nasdaq:APRI)
(http://www.apricusbio.com) announced today that Dr. Bassam Damaj, Chairman,
President and Chief Executive Officer, will present an overview of its
wholly-owned subsidiary, NexMed (USA), Inc.'s Rx and Consumer Healthcare
Divisions, at the 11th Annual Biotech in Europe ...
DGAP-News: Apricus Biosciences Receives FDA Clearance for Its Third OTC Drug Containing NexACT(R) Technology Apricus Biosciences, Inc.
31.08.2011 15:47
---------------------------------------------------------------------------
SAN DIEGO, 2011-08-31 15:47 CEST (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio' or the 'Company') (Nasdaq:APRI)
(http://www.apricusbio.com) announced today that its wholly-owned subsidiary,
NexMed USA, Inc., has received clearance from the U.S. Food and Drug
Administration ('FDA') for its third, over-the-counter ('OTC') drug,
Diphenhydramine-D(tm), containing th ...
DGAP-News: Photo Release -- Apricus Biosciences Announces FDA Clearance for Its First Anti-Fungal OTC Drug (Tolnaftate-D(TM)) Containing NexACT(R) Technology Apricus Biosciences, Inc.
18.08.2011 15:00
---------------------------------------------------------------------------
DDAIP Now Listed on U.S. Monograph for OTC Products
SAN DIEGO, 2011-08-18 15:00 CEST (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio' or the 'Company') (Nasdaq:APRI)
(http://www.apricusbio.com) announced today that its wholly owned subsidiary,
NexMed USA, has received clearance from the U.S. Food and Drug Administration
('FDA') to market its first anti-fungal, ov ...
DGAP-News: Apricus Biosciences Announces Second Quarter 2011 Financial Results Conference Call Apricus Biosciences, Inc.
11.08.2011 22:30
---------------------------------------------------------------------------
Conference Call/Webcast to be held Monday, August 15, 2011 at 10:00 a.m. ET
SAN DIEGO, 2011-08-11 22:30 CEST (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio') (Nasdaq:APRI) announced today that
management will hold a conference call to discuss its second quarter 2011
financial results and ongoing corporate activities on Monday, August 15, 2011
at 10:00 a.m. ET. T ...
DGAP-News: Apricus Biosciences to File for Market Authorization to Sell Vitaros(R) for Erectile Dysfunction in Latin America Apricus Biosciences, Inc.
08.08.2011 16:03
---------------------------------------------------------------------------
Potential Market Size for Vitaros(R) for Erectile Dysfunction in Brazil, Alone,
is Approximately $347 Million, Based on IMS Health Data (2010)
SAN DIEGO, 2011-08-08 16:03 CEST (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio') (Nasdaq:APRI) announced today that it
will file for market authorization to sell its erectile dysfunction drug,
Vitaros(r), in Latin Ameri ...
DGAP-News: Apricus Biosciences Provides Corporate Mid-Year Update Apricus Biosciences, Inc.
04.08.2011 19:37
---------------------------------------------------------------------------
SAN DIEGO, Aug. 4, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ('Apricus
Bio' or the 'Company') (Nasdaq:APRI) (http://www.apricusbio.com) announced
today a corporate mid-year update covering Company activities, expected
near-term events and comments on recent market conditions, as follows:
Vitaros(r)
The key focus of the Company's management team has been, and conti ...
DGAP-News: Apricus Biosciences Files Marketing Application for Vitaros(R) as a Treatment for Erectile Dysfunction in Switzerland Apricus Biosciences, Inc.
19.07.2011 15:57
---------------------------------------------------------------------------
SAN DIEGO, 2011-07-19 15:57 CEST (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio') (Nasdaq:APRI) announced today its
filing of a marketing application for Vitaros(r) as a treatment for patients with
erectile dysfunction ('ED') in Switzerland, with Swissmedic, the Swiss Agency
for Therapeutic Products. 'We are excited about making our third major filing
for our fla ...
DGAP-News: Apricus Biosciences' Marketing Application for Vitaros(R), for the Treatment of Erectile Dysfunction, is Accepted for Review in Europe Apricus Biosciences, Inc.
28.06.2011 16:47
---------------------------------------------------------------------------
SAN DIEGO, 2011-06-28 16:47 CEST (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio') (Nasdaq:APRI) announced today that
its marketing application for Vitaros(r), indicated for the treatment of patients
with erectile dysfunction ('ED'), has been accepted for review through the
European Decentralized Procedure ('DCP').
In connection with the DCP, on April 28, 2011, ...
DGAP-News: Apricus Bio CEO to Present Commercialization Plans for Vitaros(R) at Jefferies 2011 Global Healthcare Conference Apricus Biosciences, Inc.
03.06.2011 16:17
---------------------------------------------------------------------------
Company Presentation Moved to June 8, 2011 at 2:00pm ET
SAN DIEGO, 2011-06-03 16:17 CEST (GLOBE NEWSWIRE) --
Bassam Damaj, PhD., Chief Executive Officer of Apricus Biosciences, Inc.
('Apricus Bio') (Nasdaq:APRI) (http://www.apricusbio.com) announced today that
he will discuss plans for the commercialization of Vitaros(r), the Company's
topical erectile dysfunction drug, duri ...
DGAP-News: Apricus Biosciences Appoints Steve Martin as Senior Vice President and Chief Financial Officer Apricus Biosciences, Inc.
02.06.2011 18:00
---------------------------------------------------------------------------
SAN DIEGO, 2011-06-02 18:00 CEST (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio') (Nasdaq:APRI) today announced that
Steve Martin has been appointed Senior Vice President and Chief Financial
Officer, replacing Mark Westgate, who will serve as a consultant to the Company
during a transition period.
Mr. Martin, a certified public accountant, brings over 25 years ...
DGAP-News: Apricus Biosciences Announces Issuance of Key Patent for RayVa(TM) for Raynaud's Phenomenon in Israel Apricus Biosciences, Inc.
31.05.2011 15:55
---------------------------------------------------------------------------
Coverage Also Expands to Wound Healing, Inflammatory Skin Lesions and Certain
Skin Conditions
SAN DIEGO, 2011-05-31 15:55 CEST (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio') (Nasdaq:APRI)
(http://www.apricusbio.com) announced today that the Israeli Patent Office has
allowed and granted the Company a patent entitled, 'Topical Compositions for
Prostaglandin E1 ...
DGAP-News: Apricus Biosciences' CEO to Present at Jefferies 2011 Global Healthcare Conference Apricus Biosciences, Inc.
26.05.2011 19:32
---------------------------------------------------------------------------
SAN DIEGO, 2011-05-26 19:32 CEST (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio') (Nasdaq:APRI)
(http://www.apricusbio.com) today announced that Bassam Damaj, Ph.D., Chairman,
President and Chief Executive Officer of Apricus Bio, will present at the
Jefferies 2011 Global Healthcare Conference, being held at the Grand Hyatt
Hotel in New York City. The presentation ...
DGAP-News: Apricus Biosciences to Present at the Euro-Biotech Partnering Forum 2011 to Further Its Partnership Efforts Apricus Biosciences, Inc.
23.05.2011 19:38
---------------------------------------------------------------------------
SAN DIEGO, 2011-05-23 19:37 CEST (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio') (Nasdaq:APRI)
(http://www.apricusbio.com) today announced that Linda Smibert, Vice President,
Business Development at the Company's NexMed, USA, Inc. subsidiary, will
present at the Euro-Biotech Partnering Forum 2011 conference in Paris, France,
on Tuesday, May 24th at 10:00 am CET. ...
DGAP-News: Apricus Biosciences CEO is Interviewed on CDTV.net Apricus Biosciences, Inc.
18.05.2011 17:08
---------------------------------------------------------------------------
SAN DIEGO, 2011-05-18 17:07 CEST (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio') (Nasdaq:APRI)
(http://www.apricusbio.com) announced today that Chief Executive Officer, Dr.
Bassam Damaj, was recently interviewed by CDTV.net, a New York-based financial
network (www.cdtv.net). The interview is available at
http://www.cdtv.net/users/content/apricus-biosciences-nasd ...
DGAP-News: Apricus Biosciences Announces First Quarter 2011 Financial Results Conference Call Apricus Biosciences, Inc.
10.05.2011 15:21
---------------------------------------------------------------------------
Conference Call/Webcast to be Held Friday, May 13, 2011 at 1:00 p.m. ETSAN DIEGO, May 10, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ('Apricus
Bio') (Nasdaq:APRI) announced today that management will hold a conference call
to discuss its first quarter 2011 financial results and ongoing corporate
activities on Friday, May 13, 2011 at 1:00 p.m. ET. The Company will file ...
DGAP-News: Apricus Biosciences Requests Approval of Vitaros(R) as a Treatment for Erectile Dysfunction in Europe Apricus Biosciences, Inc.
28.04.2011 16:06
---------------------------------------------------------------------------
Current Annual Market for Erectile Dysfunction in Europe is Estimated at
Approximately $1.1 Billion
SAN DIEGO, 2011-04-28 16:06 CEST (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio') (Nasdaq:APRI) announced today that it
has filed a marketing application in Europe for Vitaros(r) as a treatment for
patients with erectile dysfunction ('ED'). Approval of the applic ...
DGAP-News: Apricus Biosciences to Present at the FSX Investor Conference in San Francisco on April 28, 2011 Apricus Biosciences, Inc.
27.04.2011 19:17
---------------------------------------------------------------------------
SAN DIEGO, April 27, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences ('Apricus
Bio') (Nasdaq:APRI) today announced that Ed Cox, Vice President Corporate
Development and Investor Relations, will present at the FSX (Financial Services
Exchange, Inc.) investors conference being held at the Ritz Carlton in San
Francisco from April 28-30, 2011. Mr. Cox's presentation is scheduled for ...
DGAP-News: Apricus Biosciences Files for Orphan Drug Designation for RayVa(TM) Apricus Biosciences, Inc.
13.04.2011 19:11
---------------------------------------------------------------------------
Drug Intended for the Treatment of Raynaud's Phenomena, Secondary to Systemic
Sclerosis
SAN DIEGO, 2011-04-13 19:11 CEST (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio') (Nasdaq:APRI) announced today its
filing with the U.S. Food&Drug Administration ('FDA') requesting orphan drug
designation for RayVa?, the Company's drug candidate indicated for the
treatme ...
DGAP-News: Apricus Biosciences' CEO Interviewed by WallStreetCorner.com Apricus Biosciences, Inc.
05.04.2011 18:36
---------------------------------------------------------------------------
SAN DIEGO, 2011-04-05 18:36 CEST (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. ('Apricus Bio') (Nasdaq:APRI)
(http://www.apricusbio.com) announced today that Chairman, President and Chief
Executive Officer, Dr. Bassam Damaj, was recently interviewed by
WallStreetCorner.com, a New York-based financial publication. The interview is
available at http://wallstreetcorner.com/daily ...
DGAP-News: Apricus Biosciences Expands Patent Coverage in Mexico for Its Erectile Dysfunction Drug, Vitaros(R) Apricus Biosciences, Inc.
31.03.2011 16:41
---------------------------------------------------------------------------
Current Annual Market for Erectile Dysfunction in Mexico is Estimated at
Between $175 to $200 Million
SAN DIEGO, 2011-03-31 16:41 CEST (GLOBE NEWSWIRE) --Apricus Biosciences, Inc. ('Apricus Bio') (Nasdaq:APRI), announced today that
the Mexican Patent Office ('MPO') will grant an additional patent for Vitaros(r),
the Company's topical alprostadil-based cream for the treatmen ...
DGAP-News: Apricus Biosciences Adopts Shareholder Rights Plan Apricus Biosciences, Inc.
24.03.2011 14:53
---------------------------------------------------------------------------
SAN DIEGO, 2011-03-24 14:53 CET (GLOBE NEWSWIRE) --Apricus Biosciences, Inc. ('Apricus Bio') (Nasdaq:APRI) announced today that
its Board of Directors (the 'Board') has adopted a Shareholder Rights Plan (the
'Plan'). The purpose of the Plan is to better allow the Board to protect
shareholder interests in realizing fair value in the event of an attempted
takeover of the Comp ...
DGAP-News: Apricus Biosciences Announces Formation of Clinical Advisory Board as Part of Its Plans to Further the Clinical Development of Femprox(R) Apricus Biosciences, Inc.
15.03.2011 15:08
---------------------------------------------------------------------------
SAN DIEGO, 2011-03-15 15:08 CET (GLOBE NEWSWIRE) --Apricus Biosciences, Inc., ('Apricus Bio') (Nasdaq:APRI) today announced the
formation of a Male and Female Sexual Dysfunction Clinical Advisory Board
('Sexual Dysfunction Clinical Advisory Board') as a first step to further the
development of its product Femprox(r), for female sexual arousal disorder
('FSAD'). The Sexual D ...
DGAP-News: Apricus Biosciences to Present at the Bio-Europe Spring 2011 Conference Apricus Biosciences, Inc.
10.03.2011 15:57
---------------------------------------------------------------------------
SAN DIEGO, 2011-03-10 15:57 CET (GLOBE NEWSWIRE) --Apricus Biosciences, Inc. ('Apricus Bio') (Nasdaq:APRI)
(http://www.apricusbio.com) today announced that Linda Smibert, Vice President,
Business Development at the Company's NexMed, USA, Inc. ('NexMed, USA')
subsidiary, will present at the Bio-Europe Spring 2011 conference in Milan,
Italy, on Wednesday, March 16th at 11:00 ...
DGAP-News: Apricus Biosciences Announces Removal of Auditor's 'Going Concern' Opinion From Its 2010 Form 10-K and Increased Cash Reserves Apricus Biosciences, Inc.
08.03.2011 15:57
---------------------------------------------------------------------------
SAN DIEGO, 2011-03-08 15:57 CET (GLOBE NEWSWIRE) --Apricus Biosciences, Inc. ('Apricus Bio') (Nasdaq:APRI) announced today that
the going concern paragraph has been removed from its audit opinion contained
in its upcoming filing of Form 10-K for the year ended December 31, 2010 and
the Company has increased cash reserves in 2010 compared to the previous year.
Apricus Bio wi ...
DGAP-News: Apricus Biosciences Announces Expanded European Patent Coverage for MycoVa(TM) for Nail Fungus Apricus Biosciences, Inc.
01.03.2011 15:14
---------------------------------------------------------------------------
SAN DIEGO, 2011-03-01 15:14 CET (GLOBE NEWSWIRE) --Apricus Biosciences, Inc. ('Apricus Bio') (Nasdaq:APRI) announced today that
the European Patent Office ('EPO') will grant a patent for the company's
MycoVa? product for treating onychomycosis (commonly referred to as nail
fungus).
The European Patent Office recently issued a 'notice of allowance' for the
Company's patent ...
DGAP-News: Apricus Biosciences and FDA Initiate PrevOnco(TM) SPA Phase III Clinical Protocol Discussion Apricus Biosciences, Inc.
17.02.2011 15:11
---------------------------------------------------------------------------
SAN DIEGO, 2011-02-17 15:11 CET (GLOBE NEWSWIRE) --Apricus Biosciences, Inc. ('Apricus Bio') (Nasdaq:APRI), announced today that
it is currently in discussions with the U.S. Food and Drug Administration
('FDA') relating to the PrevOnco? Special Protocol Assessment ('SPA') Phase III
protocol submitted by the Company in December 2010.
In the first response received by Apric ...
DGAP-News: Apricus Biosciences and Neopharm Group Sign Licensing Agreement for Vitaros(R) in Israel for up to $4.35 Million, Plus Royalties Apricus Biosciences, Inc.
14.02.2011 16:14
---------------------------------------------------------------------------
SAN DIEGO, 2011-02-14 16:14 CET (GLOBE NEWSWIRE) --Apricus Biosciences, Inc. ('Apricus Bio') (Nasdaq:APRI), announced today that
it has entered into a licensing agreement granting Neopharm Group ('Neopharm')
the exclusive rights to market and sell Vitaros(r), Apricus Bio's treatment for
erectile dysfunction ('ED') and, when and if available, its formulation for the
treatmen ...
DGAP-News: Apricus Biosciences, Inc. Press Release Apricus Biosciences, Inc.
19.01.2011 17:41
---------------------------------------------------------------------------
Apricus Biosciences Reports Additional Analysis Showing That MycoVa(TM) is as
Effective for the Treatment of Nail Fungus as the Current European Standard of
Care for Topical Therapy, Loceryl(R)
SAN DIEGO, Jan. 19, 2011 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc.
('Apricus Bio') (Nasdaq:APRI) today announced that an additional analysis
conducted on behalf of the Company ha ...
Tagesgeld-Konditionen
Pressemitteilungen der Druckerei WIRmachenDRUCK finden Sie auf wir-machen-druck.de unter Aktuelles.
Hochwertiges und günstiges Spielzeug, sowie Bastelbedarf und Bastelmaterial gibt es im didagoshop.
Moderne Badmöbel und viele tolle Möbel für Ihr Zuhause.
Für ein effektives und erfolgreiches Direktmarketing. Adressen kaufen bei Best Adress.
Mit einem einfachen Strompreisvergleich können Sie jeden Monat sparen.
Günstige Kredite für Selbstständige und Freiberufler - auch in schwierigen Fällen!
Kfz Ersatzteile von 100Pro-Ersatzteile.de, Autoteile in Erstausrüsterqualität.
RSS Feed
